Latest & greatest articles for copd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd

81. Telemonitoring in Chronic Obstructive Pulmonary Disease (CHROMED). A Randomized Clinical Trial Full Text available with Trip Pro

Telemonitoring in Chronic Obstructive Pulmonary Disease (CHROMED). A Randomized Clinical Trial Early detection of chronic obstructive pulmonary disease (COPD) exacerbations using telemonitoring of physiological variables might reduce the frequency of hospitalization.To evaluate the efficacy of home monitoring of lung mechanics by the forced oscillation technique and cardiac parameters in older patients with COPD and comorbidities.This multicenter, randomized clinical trial recruited 312 (...) patients with Global Initiative for Chronic Obstructive Lung Disease grades II to IV COPD (median age, 71 yr [interquartile range, 66-76 yr]; 49.6% grade II, 50.4% grades III-IV), with a history of exacerbation in the previous year and at least one nonpulmonary comorbidity. Patients were randomized to usual care (n = 158) or telemonitoring (n = 154) and followed for 9 months. All telemonitoring patients self-assessed lung mechanics daily, and in a subgroup with congestive heart failure (n = 37) cardiac

2018 EvidenceUpdates

82. myAIRVO2 for the treatment of chronic obstructive pulmonary disease

airways (tracheostomy patients). Other features of myAIRVO2 are that it allows clinicians to titrate flow (from 10 to 60 litres/min on adult mode) and oxygen independently from one another and does not need a sealed interface. The product is marketed as AIRVO2 and myAIRVO2. myAIRVO2 is a device that is being used in the home or other domiciliary care environment. This briefing focuses on myAIRVO2 delivering nasal high-flow therapy for treating chronic obstructive pulmonary disease (COPD), including (...) in a community setting. Innovations myAIRVO2 differs from standard respiratory gas devices in being designed to allow the delivery of nasal high-flow therapy in a community setting. It also uses room air, removing the need for piped medical air, and humidifies the delivered air to reduce the risk of dryness and trauma to the upper airway mucosa. Current care pathway The NICE guideline on chronic obstructive pulmonary disease recommends treatment options including smoking cessation, inhaled therapy, oral

2018 National Institute for Health and Clinical Excellence - Advice

83. Patient-facing Technology for Identification of COPD in Primary Care. Full Text available with Trip Pro

Patient-facing Technology for Identification of COPD in Primary Care. The proliferation of mobile devices and emergence of interoperable 'mHealth' apps is accelerating development and deployment of patient-facing risk assessments in primary care. The present study describes a user-centered design and an agile development approach to creation of an app for assessing lungfunction as part of a randomized controlled trial for the   dentification of chronic obstructive lung disease in primary (...) care.Seventeen patients recruited from a hospital-based, ambulatory family medicine clinic agreed to be videotaped while using the app, Lung Age, on a first-generation iPad prior to their provideR encounter. Subsequently, participants were interviewed using a semi-structured interview guide upon exiting their medical visit.Observational data indicated that participants took advantage of the portability and flexibility of the tablet device in the exam room to engage with the Lung Age app with the optionto

2018 Journal of innovation in health informatics Controlled trial quality: uncertain

84. Use of adjunct cardiovascular therapy in patients hospitalised for acute exacerbations of COPD Full Text available with Trip Pro

Use of adjunct cardiovascular therapy in patients hospitalised for acute exacerbations of COPD In real-life practice, acute exacerbation of COPD is often treated as a cardiopulmonary syndrome http://ow.ly/uAnk30luMYz.

2018 ERJ open research

85. Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial Full Text available with Trip Pro

with chronic obstructive pulmonary disease (COPD).This 26-week, randomized, double-blind, triple-dummy study assessed the direct change from long-term triple therapy to indacaterol/glycopyrronium (110/50 μg once daily) or continuation of triple therapy (tiotropium [18 μg] once daily plus combination of salmeterol/fluticasone propionate [50/500 μg] twice daily) in nonfrequently exacerbating patients with moderate-to-severe COPD. Primary endpoint was noninferiority on change from baseline in trough FEV1 (...) Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial There are no studies on withdrawal of inhaled corticosteroids in patients on long-term triple therapy in the absence of frequent exacerbations.To evaluate the efficacy and safety of direct de-escalation from long-term triple therapy to indacaterol/glycopyrronium in nonfrequently exacerbating patients

2018 EvidenceUpdates

86. Effects of upper limb resistance exercise on aerobic capacity, muscle strength, and quality of life in COPD patients: a randomized controlled trial (Abstract)

Effects of upper limb resistance exercise on aerobic capacity, muscle strength, and quality of life in COPD patients: a randomized controlled trial To evaluate the effects of upper limb resistance exercise on the functional capacity, muscle function, and quality of life in patients with chronic obstructive pulmonary disease.Clinical School of Physiotherapy in a Public University of Brazil.58 patients were recruited; of these, 7 were excluded and 51 individuals were enrolled.Control group (...) performed warm-up, aerobic exercise, inspiratory muscle training, and session stretching, followed by massage therapy. The treatment group performed warm-up, aerobic exercise, inspiratory muscle training, three sets of upper limb resistance exercise, and session stretching, followed by massage therapy. Total three sessions per week for eight weeks.6-minute walk test, respiratory and peripheral muscle strength, dyspnea, and quality of life. Normality of the data was tested using the Shapiro-Wilk test

2018 EvidenceUpdates

87. Impact of coexistent chronic obstructive pulmonary disease on the survival of patients with small cell lung cancer receiving chemotherapy Full Text available with Trip Pro

Impact of coexistent chronic obstructive pulmonary disease on the survival of patients with small cell lung cancer receiving chemotherapy While there is growing interest in the correlation between chronic obstructive pulmonary disease (COPD) and non-small cell lung cancer, very few studies have examined the interaction between COPD and small cell lung cancer (SCLC). Therefore, the aim of this study was to examine the impact of COPD on the survival of patients with SCLC.The medical records (...) of 110 patients with SCLC who received chemotherapy from July 2006 until April 2014 were retrospectively examined. The overall survival (OS) and progression-free survival (PFS) rates of spirometry-diagnosed COPD and non-COPD groups were compared. Predictors for poorer survival were analyzed using Cox proportional hazards regression.Of the 110 SCLC patients, 57 (51.8%) had coexistent COPD. The median OS for the COPD group was 11.6 months and for the non-COPD group was 11.2 months (log-rank test, P

2018 Thoracic cancer

88. Determinants and outcomes of change in physical activity in COPD Full Text available with Trip Pro

Determinants and outcomes of change in physical activity in COPD Determinants of change in physical activity and outcomes of physical activity promotion are unclear. In this secondary analysis of a randomised controlled trial of a physical activity intervention, we assess predictors of change in physical activity and the effects of increasing physical activity on chronic obstructive pulmonary disease (COPD) measures. Physical activity was promoted in 94 subjects with COPD using the Omron HJ (...) day). Linear regression models explored predictors of change in physical activity and assessed the effect of response on changes in COPD measures. The cohort of responders (n=62) and nonresponders (n=32) had mean FEV1 1.89±0.64 L (63±22% predicted). Baseline steps per day, diagnosis of depression, social support, oxygen use and season significantly predicted change in daily step count. Responders had increases in physical activity (2038 steps per day), FEV1 (308 mL) and 6MWT distance (43.6 m

2018 ERJ open research Controlled trial quality: uncertain

89. Circulating eosinophil levels do not predict severe exacerbations in COPD: a retrospective study Full Text available with Trip Pro

Circulating eosinophil levels do not predict severe exacerbations in COPD: a retrospective study Whether the level of circulating eosinophils in chronic obstructive pulmonary disease (COPD) patients can predict the risk of exacerbations of COPD (ECOPD) or response to treatment is debated. Here, we evaluate the prevalence of elevated eosinophils in COPD patients and its relationship with severe ECOPD requiring hospitalisation. We retrospectively reviewed the charts of COPD patients hospitalised (...) patients, 121 had one or more ECOPD during the year after the index event. The prevalence of eosinophils ≥2% was 72% in ECOPD patients and 71% in controls (p=0.93). Among ECOPD patients, eosinophil levels ≥2%, ≥4% or ≥300 cells·μL-1, either when clinically stable or during hospitalisation, did not show a significant association with the rate of recurrent severe exacerbations. The severity of airflow limitation was associated with recurrent exacerbations, but inhaled corticosteroid treatment

2018 ERJ open research

90. COPD exacerbations

exacerbations : a European Respiratory Society/American Thoracic Society guideline Jadwiga A. Wedzicha (ERS co-chair) , Marc Miravitlles , John R. Hurst , Peter M.A (...) of chronic obstructive pulmonary disease ( COPD ) exacerbations . Comprehensive evidence syntheses, including meta-analyses, were performed to summarise all available evidence relevant to the Task Force's questions. The evidence was appraised using the Grading of Recommendations, Assessment, Development and Evaluation approach (...) Week 08, Ovid 2011 12. Management of COPD exacerbations : a European Respiratory Society/American Thoracic Society guideline. This document provides clinical recommendations for treatment of chronic obstructive pulmonary disease ( COPD ) exacerbations.Comprehensive evidence syntheses, including meta-analyses, were performed to summarise all available evidence relevant to the Task Force's questions. The evidence was appraised using the Grading of Recommendations, Assessment, Development

2018 Trip Latest and Greatest

91. COPD

according to the progression of the disease. Chronic obstructive pulmonary disease or COPD is a chronic inflammation of the respiratory tract, with the gradual and partially irreversible deterioration of the airways. Patients generally suffer from a chronic cough 2016 14. Overview of COPD Overview of COPD - Summary of relevant conditions | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Overview of COPD Last reviewed: August 2018 Last updated: June 2018 (...) Introduction Chronic obstructive pulmonary disease ( COPD ) is a disorder that is usually progressive, characterised by airflow limitation that is not fully reversible. Sutherland ER, Cherniack RM. Management of chronic obstructive pulmonary disease . N Engl J Med. 2004;350 (...) :2689-2697. http://www.ncbi.nlm.nih.gov/pubmed/15215485?tool=bestpractice.com Around 90% of cases of COPD are caused by cigarette smoking; other strong risk factors include more advanced age (may be related to longer period

2018 Trip Latest and Greatest

92. COPD Disease Education in Pulmonary Rehabilitation: A Workshop Report

%(greaterunderstanding, con?dence etc.). Test retest Section A ICC range=0.87–0.96 7 Section B, Wilcoxon signed rank test (no difference) P.0.05 Cronbach’s a range=0.78– 0.95 De?nition of abbreviations: BCKQ=Bristol COPD Knowledge Questionnaire; COPD=chronic obstructive pulmonary disease; COPD-Q=COPD Knowledge Questionnaire; ICC=intraclass correlation coef?cient; LINQ=Lung Information Needs Questionnaire; UCOPD=Understanding COPD questionnaire. WORKSHOP REPORT 772 AnnalsATS Volume 15 Number 7 | July 2018 content (...) COPD Disease Education in Pulmonary Rehabilitation: A Workshop Report WORKSHOPREPORT Chronic Obstructive Pulmonary Disease Education in Pulmonary Rehabilitation An Of?cial American Thoracic Society/Thoracic Society of Australia and New Zealand/Canadian Thoracic Society/British Thoracic Society Workshop Report Felicity C. Blackstock, Suzanne C. Lareau, Linda Nici, Richard ZuWallack, Jean Bourbeau, Maria Buckley, StevenJ.Durning,TanjaW.Ef?ng,EllenEgbert,RogerS.Goldstein,William Kelly,AnnemarieLee

2018 American Thoracic Society

93. Sleep-disordered Breathing in Patients with COPD

. 17. Biselli P, Grossman PR, Kirkness JP, Patil SP, Smith PL, Schwartz AR, et al. The effect of increased lung volume in chronic obstructive pulmonary disease on upper airway obstruction during sleep. J Appl Physiol (1985) 2015;119:266–271. 18. Soler X, Diaz-Piedra C, Ries AL. Pulmonary rehabilitation improves sleep quality in chronic lung disease. COPD 2013;10: 156–163. 19. Kohli P, Pinto-Plata V, Divo M, Malhotra A, Harris RS, Lazaar A, et al. Functional capacity, health status, and in?ammatory (...) , the severity of inspiratory and expiratory ?ow limitation, and the presence of hyperin?ation during sleep (e.g., pneumotachography, nasal pressure signaling, and ?ow sensors) in patients with COPD. Introduction Chronic obstructive pulmonary disease (COPD) is a major source of morbidity, mortality, and healthcare costs. It is increasing in epidemic proportions because of the aging population, indoor and outdoor air pollution, historical smoking trends, and other factors (1). Efforts to slow the progression

2018 American Thoracic Society

94. Factors associated with hospital emergency readmission and mortality rates in patients with heart failure or chronic obstructive pulmonary disease: a national observational study Full Text available with Trip Pro

Factors associated with hospital emergency readmission and mortality rates in patients with heart failure or chronic obstructive pulmonary disease: a national observational study Factors associated with hospital emergency readmission and mortality rates in patients with heart failure or chronic obstructive pulmonary disease: a national observational study Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry (...) - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Factors predicting mortality and readmission following admission with heart failure or chronic obstructive pulmonary disease were identified at both patient and hospital levels. {{author}} {{($index , , , & . Alex Bottle 1, * , Kate Honeyford 1 , Faiza

2018 NIHR HTA programme

95. [Nutritional and functional state of patients with chronic obstructive pulmonary disease: effects of oral nutritional supplementation (OFOS study)]. Full Text available with Trip Pro

[Nutritional and functional state of patients with chronic obstructive pulmonary disease: effects of oral nutritional supplementation (OFOS study)]. Weight loss and malnutrition are associated with a worse prognosis of chronic obstructive pulmonary disease (COPD).The main objective of the OFOS study was to assess the efficacy and tolerability of a new nutritional oral formula in adults with COPD with weight loss or malnutrition.Prospective, single-centre, randomized, open-label and controlled (...) trial conducted in Lima (Peru). A total of 99 outpatients of both sexes were included (control [GC]: 49; supplement [GS]: 50), aged from 18 to 80 years old, who had been diagnosed with COPD and that suffered from malnutrition or involuntary weight loss during the last months. Nutritional, functional and quality of life (QoL) variables were evaluated during a three-month intervention.At three months, there was an increase of body mass index (BMI) and fat free mass index (FFMI) significantly higher

2018 Nutricion hospitalaria Controlled trial quality: uncertain

96. Microbial and host immune factors as drivers of COPD Full Text available with Trip Pro

Microbial and host immune factors as drivers of COPD Compartmentalisation of the respiratory tract microbiota in patients with different chronic obstructive pulmonary disease (COPD) severity degrees needs to be systematically investigated. In addition, it is unknown if the inflammatory and emphysematous milieux in patients with COPD are associated with changes in the respiratory tract microbiota and host macrophage gene expression. We performed a cross-sectional study to compare non-COPD (...) controls (n=10) to COPD patients (n=32) with different disease severity degrees. Samples (n=187) were obtained from different sites of the upper and lower respiratory tract. Microbiota analyses were performed by 16S ribosomal RNA gene sequencing and host gene expression analyses by quantitative real-time PCR of distinct markers of bronchoalveolar lavage cells. Overall, the microbial communities of severe COPD (Global Initiative for Chronic Obstructive Lung Disease (GOLD) grade 3/4) patients clustered

2018 ERJ open research

97. The Impact of Listening to Music During a High-Intensity Exercise Endurance Test in People With COPD (Abstract)

The Impact of Listening to Music During a High-Intensity Exercise Endurance Test in People With COPD In people with COPD, dyspnea is the primary symptom limiting exercise tolerance. One approach to reducing dyspnea during exercise is through music listening. A constant speed endurance test reflects a high-intensity aerobic exercise training session, but whether listening to music affects endurance time is unknown. This study aimed to determine the effects of listening to music during a constant (...) speed endurance test in COPD.Participants with COPD completed two endurance walk tests, one with and one without listening to self-selected music throughout the test. The primary outcome was the difference in endurance time between the two conditions. Heart rate, percutaneous oxygen saturation, dyspnea, and rate of perceived exertion were measured before and after each test.Nineteen participants (mean [SD]: age, 71 [8] years; FEV1, 47 [19] % predicted) completed the study. Endurance time was greater

2018 EvidenceUpdates

98. Intensified Therapy with Inhaled Corticosteroids and Long-Acting beta2-Agonists at the Onset of Upper Respiratory Tract Infection to Prevent Chronic Obstructive Pulmonary Disease Exacerbations. A Multicenter, Randomized, Double-Blind, Placebo-controlled T (Abstract)

Intensified Therapy with Inhaled Corticosteroids and Long-Acting beta2-Agonists at the Onset of Upper Respiratory Tract Infection to Prevent Chronic Obstructive Pulmonary Disease Exacerbations. A Multicenter, Randomized, Double-Blind, Placebo-controlled T The efficacy of intensified combination therapy with inhaled corticosteroids (ICS) and long-acting β2-agonists (LABA) at the onset of upper respiratory tract infection (URTI) symptoms in chronic obstructive pulmonary disease (COPD (...) analysis, effect size was modified by disease severity, fractional exhaled nitric oxide, and the body mass index-airflow obstruction-dyspnea, and exercise score. Compared with the stable period, evidence of at least one virus was significantly more common at URTI, 10 days after URTI, and at exacerbation.Intensified combination therapy with ICS/LABA for 10 days at URTI onset did not decrease the incidence of any COPD exacerbation but prevented severe exacerbation. Patients with more severe disease had

2018 EvidenceUpdates

99. COPD

COPD Evidence Maps - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading (...) read , explaining issues with the system. NOTE : Chrome is the best browser to use! To get started, type a condition/disease into the search box above. Here are some examples to get you started: Building Evidence Map X Axis Alphabetically Risk of bias No. Articles Sample Size Risk of bias any low Minimum sample size Apply Follow us: © 2019 Trip Database Ltd. company number 04316414. Trip is proud to be made in the UK.

2018 Trip Evidence Maps

100. Self management of patients with mild COPD in primary care: randomised controlled trial. Full Text available with Trip Pro

Self management of patients with mild COPD in primary care: randomised controlled trial. To evaluate the effectiveness of telephone health coaching delivered by a nurse to support self management in a primary care population with mild symptoms of chronic obstructive pulmonary disease (COPD).Multicentre randomised controlled trial.71 general practices in four areas of England.577 patients with Medical Research Council dyspnoea scale scores of 1 or 2, recruited from primary care COPD registers (...) COPD.The primary outcome was health related quality of life at 12 months using the short version of the St George's Respiratory Questionnaire (SGRQ-C).The intervention was delivered with good fidelity: 86% of scheduled calls were delivered; 75% of patients received all four calls. 92% of patients were followed-up at six months and 89% at 12 months. There was no difference in SGRQ-C total score at 12 months (mean difference -1.3, 95% confidence interval -3.6 to 0.9, P=0.23). Compared with patients

2018 BMJ Controlled trial quality: predicted high